The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

Lung cancer in patients who have never smoked — an emerging disease

Novel mutations in a second primary gastric cancer in a patient treated for primary colon cancer, World Journal of Surgical Oncology

Rare molecular subtypes of lung cancer

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities

Utility of needle biopsy in centrally located lung cancer for genome analysis: a retrospective cohort study, BMC Pulmonary Medicine

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates - Sentana-Lledo - Translational Lung Cancer Research

The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. - Abstract - Europe PMC

Frontiers LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

Full article: The CLIP1–LTK fusion: anew oncogenic driver in non-small-cell lung cancer?

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities

The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. - Abstract - Europe PMC